Evidence map›Paper›PMID 36682141›Full record

ArticleCancer treatment and research communications2023

Cervical cancer screening in HIV-endemic countries: An urgent call for guideline change.

Surbhi Grover, Rohini Bhatia, Tara M Friebel-Klingner, Anikie Mathoma, Peter Vuylsteke, Salman Khan, Tlotlo Ralefala, Leabaneng Tawe, Lisa Bazzett-Matabele, Barati Monare and 2 more

Abstract read
In one paragraph

Article in Cancer treatment and research communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Surbhi GroverRadiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Electronic address: Surbhi.grover@pennmedicine.upenn.edu.
Rohini BhatiaJohns Hopkins University, Department of Radiation Oncology and Molecular Sciences, Baltimore, MD,USA.
Tara M Friebel-KlingnerJohns Hopkins Bloomberg School of Public Health, Department of Epidemiology, Baltimore, MD,USA.
Anikie MathomaFaculty of Medicine, University of Botswana, Gaborone, Botswana.
Peter VuylstekeFaculty of Medicine, University of Botswana, Gaborone, Botswana.
Salman KhanRadiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Tlotlo RalefalaDepartment of Oncology, Princess Marina Hospital,Gaborone, Botswana.
Leabaneng TaweBotswana-UPenn Partnership, Gaborone, Botswana.
Lisa Bazzett-MatabeleDepartment of Obstetrics & Gynecology, Faculty of Medicine, University of Botswana, Gaborone, Botswana; Department of Obstetrics & Gynecology, Yale University School of Medicine, New Haven, CT, United States of America.
Barati MonareBotswana-UPenn Partnership, Gaborone, Botswana.
Rebecca LuckettDepartment of Obstetrics & Gynecology, Faculty of Medicine, University of Botswana, Gaborone, Botswana; Beth Israel Deaconess Medical Center, Boston, MA, United States of America.
Doreen Ramogola-MasireDepartment of Obstetrics & Gynecology, Faculty of Medicine, University of Botswana, Gaborone, Botswana.

Funding

Shared Resources CoreU54CA190158 · NCI · UNIVERSITY OF PENNSYLVANIA · PI ROBERTSON, ERLE S. · 2014 to 2023
$4.2M
Prognostic value of quantitative HPV viral load in determining cervical cancer treatment response and recurrenceK08CA230170 · NCI · UNIVERSITY OF PENNSYLVANIA · PI GROVER, SURBHI · 2019 to 2023
$1.4M
Evaluation of triage strategies and screening intervals in a human papillomavirus based cervical cancer screening program in women living with human immunodeficiency virus in BotswanaK08CA271949 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Rebecca Luckett · 2022 to 2026
$1.3M
NCI NIH HHS K08 CA230170NCI NIH HHS K08 CA271949NCI NIH HHS U54 CA190158
6 · The paper itself

Abstract

Women living with HIV (WLWH) are at an increased risk of developing HPV-related high grade cervical dysplasia and cervical cancer. Prior World Health Organization (WHO) screening guidelines recommended starting screening at age 30. We assessed characteristics of women diagnosed with cervical cancer to further inform and refine screening guidelines. We prospectively enrolled women diagnosed with cervical cancer from January 2015 to March 2020 at two tertiary hospitals in Gaborone, Botswana. We performed chi-square and ANOVA analyses to evaluate the association between age upon diagnosis and HIV status, CD4 count, viral load, and other sociodemographic and clinical factors. Data were available for 1130 women who were diagnosed with cervical cancer and 69.3% were WLWH. The median age overall was 47.9 (IQR 41.2-59.1), 44.6 IQR: 39.8 - 50.9) among WLWH, and 61.2 (IQR 48.6-69.3) among women living without HIV. There were 1.3% of women aged <30 years old, 19.1% were 30-39 and 37.2% were 40-49. Overall, 20.4% (n = 231) of cancers were in women <40 years. Age of cervical cancer diagnosis is younger in countries with higher HIV prevalence, like Botswana. Approximately 20% of the patients presented with cancer at <40 years of age and would have likely benefited from screening 10 years prior to cancer diagnosis to provide an opportunity for detection and treatment of pre-invasive disease.

Indexed as

HIV InfectionsPapillomavirus InfectionsUterine Cervical DysplasiaUterine Cervical NeoplasmsAdultEarly Detection of CancerFemaleHumansCervical cancerGlobal healthGuidelinesHIVPreventionScreening

Identifiers

PMID36682141
PMCPMC9999385

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.